Chronic Pain Market Intelligence: Epidemiology Trends and Forecast Through 

DelveInsight's comprehensive report on "Chronic Pain Market Insights, Epidemiology and Market Forecast - 2034" delivers extensive understanding of Chronic Pain, encompassing historical and projected epidemiology alongside market dynamics in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Unlock key insights into the Chronic Pain Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chronic Pain Market Size

Key Highlights from the Market Report

• On 28 October 2025, Sangamo Therapeutics initiated a first-in-human investigation to test an experimental treatment approach called "gene therapy." The primary objective is to establish safety and tolerability profiles. The secondary objective is to assess whether it reduces refractory pain levels associated with SFN disease. The gene will be introduced into cellular systems using a specialized delivery mechanism called a vector.

• The total 7MM Chronic Pain Prevalent Cases in 2023 showed the United States accounting for the highest case numbers.

• Among the EU4 and the UK, the highest number of Chronic Pain prevalent cases were documented in the UK, representing approximately 30%.

• Chronic pain prevalence increased with advancing age and demonstrated higher rates among individuals in the 45-64 years age cohort.

• Approximately 70% of chronic pain cases in the United States in 2023 fall within moderate to severe severity-specific categories.

• Key pharmaceutical developers include AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.

• Notable investigational therapies comprise Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and additional candidates.

Stay ahead in the competitive landscape of the Chronic Pain Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chronic Pain Treatment Market Size

Epidemiological Segmentation in the 7MM

• Total Chronic Pain Prevalent Cases

• Total Chronic Pain Diagnosed Cases

• Chronic Pain Severity-specific Cases

• Chronic Pain Age-specific Cases

• Chronic Pain Cause-specific Cases

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Prevalence

Chronic Pain Marketed Therapeutics

JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International JOYCLU represents a formulation wherein hyaluronic acid and diclofenac (an anti-inflammatory agent) are chemically bonded utilizing Seikagaku's proprietary technology. It is engineered to release diclofenac through hydrolysis within the joint. Symptom improvement in osteoarthritis (knee joint and hip joint) is anticipated by administering JOYCLU into the joint cavity once every 4 weeks. JOYCLU represents Japan's first joint function improvement agent for treating hip joint osteoarthritis.

ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an intra-articular injection designed to manage osteoarthritis pain in the knee. ZILRETTA represents Flexion's innovative, proprietary, sustained-release formulation composed of triamcinolone acetonide (TA) embedded within a biodegradable PLGA matrix that extends residence time in the joint for treating mild-to-moderate knee OA. ZILRETTA obtained FDA approval in October 2017.

Chronic Pain Emerging Therapeutics

ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals Pentosan polysulfate sodium (PPS) represents a semi-synthetic compound manufactured from European beech tree wood chips. Extracted glucuronoxylans undergo sulfation to produce a negatively charged product that mimics glycosaminoglycans (GAGs). GAGs are complex carbohydrates that perform regulatory functions throughout the body by interacting with proteins involved in inflammatory processes. Key characteristics of PPS activity include its anti-inflammatory and tissue regenerative properties, alongside its mild anti-thrombotic activity.

TNX-102 SL: Tonix Pharmaceuticals TNX-102 SL, a sublingual tablet containing 2.8 mg of cyclobenzaprine HCl, is administered nightly for fibromyalgia treatment. Its rapid absorption profile and reduced production of a long-lasting active metabolite enhance therapeutic effectiveness. This patented formulation optimizes cyclobenzaprine delivery to improve sleep quality while minimizing residual effects. TNX-102 SL, a centrally-acting analgesic, alleviates pain by enhancing sleep quality. It is currently advancing through mid-Phase III development for fibromyalgia management.

Discover the future of Chronic Pain Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chronic Pain Market Drivers and Barriers

Pharmaceutical Market Landscape

Currently, multiple medication classes are utilized in chronic pain management, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic therapeutic approaches for chronic pain can encompass exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other interventions. Several approved therapeutics exist for chronic pain treatment including EMGALITY (galcanezumab-gnlm), AIMOVIG (erenumab), and AJOVY (fremanezumab), among others.

Market Forecast Outlook

Key Chronic Pain Companies including Paradigm Biopharmaceuticals, Centrexion Therapeutics, Tonix Pharmaceuticals, and others are evaluating their lead candidates across different clinical development stages. They aim to investigate their products for Chronic Pain treatment. According to DelveInsight's analysis, Chronic Pain Market Growth is anticipated to be primarily driven by increasing Chronic Pain prevalence, enhanced awareness and treatment access, alternative options (such as novel therapeutic agents) to addictive opioids, holistic treatment approaches, organizational efforts, and upsurge in the geriatric population.

Explore the dynamics of the Chronic Pain Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chronic Pain Ongoing Clinical Trials Analysis

Report Scope

• Geographic Coverage:Global

• Study Period: 2020-2034

• Featured Companies: AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others

• Pipeline Therapies: Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Additional Coverage: Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Chronic Pain Market Overview at a Glance

4. Executive Summary of Chronic Pain

5. Key events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed Products

10. Emerging Therapies

11. Chronic Pain: The Seven Major Markets Analysis

12. SWOT Analysis

13. Unmet Needs

14. KOL Views

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com